Why the study?
Does clopidogrel treatment affect platelet reactivity and thrombogenicity differently in diabetic versus non-diabetic patients undergoing elective coronary stenting?
Does clopidogrel treatment affect platelet reactivity and thrombogenicity differently in diabetic versus non-diabetic patients undergoing elective coronary stenting?
Diabetic patients undergoing PCI exhibit higher platelet reactivity despite standard maintenance or loading doses of clopidogrel compared to non-diabetic patients, highlighting a suboptimal response to standard dual antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Diabetics show higher on-clopidogrel platelet reactivity after stenting; hypothesis-generating for tailored regimens, prospective trials needed before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Singla et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: